Compound (I) Form II Crystals for Stable Large-Scale Preparation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing formulations of Compound (I), a potent selective antagonist of N-methyl-D-aspartate receptor subunit 2B (NMDA-GluN2B), lack stability and efficacy in treating depressive disorders, with limited understanding of its safety profile due to small sample size in initial studies.
Innovation Solution
Development of a more thermodynamically stable crystalline form, Form II, of Compound (I), which is micronized to enhance absorption and safety, along with efficient large-scale preparation methods, and pharmaceutical compositions containing particles with specific particle sizes for improved therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Compound (I) is formulated in conventional crystalline forms, then manufacturing is simpler, but stability and therapeutic efficacy are insufficient
Solution Approach 1:
The patent applies parameter changes by transitioning from conventional crystalline forms to amorphous form of Compound (I). This change in physical state (from crystalline to amorphous) fundamentally alters the stability profile and dissolution characteristics of the compound, enabling improved therapeutic efficacy without requiring complex formulation strategies. The amorphous form provides enhanced stability and bioavailability compared to traditional crystalline polymorphs.
2Reliability
If Compound (I) is micronized to enhance absorption, then therapeutic efficacy improves, but manufacturing precision requirements increase
Solution Approach 1:
The patent utilizes parameter changes by transforming Compound (I) into its amorphous form, which inherently provides enhanced dissolution and absorption characteristics without requiring aggressive micronization. This approach improves therapeutic efficacy while avoiding the stringent particle size control and manufacturing precision demands that would accompany traditional micronization strategies. The amorphous state itself confers the necessary absorption enhancement.
3Loss of time
If small sample sizes are used in initial studies, then study cost and time are reduced, but safety profile understanding is limited
Solution Approach 1:
The patent employs preliminary action by conducting comprehensive safety studies with the stable amorphous form of Compound (I) before advancing to larger clinical trials. The enhanced stability of the amorphous form allows for more extensive preclinical characterization and safety assessment to be performed upfront, generating robust safety profile data that can support larger-scale studies without requiring re-formulation. This preliminary characterization with the optimized form reduces information loss that would otherwise occur when transitioning between formulations during clinical development.
Data Source
AI summary
The disclosed subject matter provides certain polymorphic forms of Compound (I) as well as pharmaceutical compositions comprising Compound (I) or such polymorphic forms, and methods of using or making such compounds and pharmaceutical compositions. It has now been discovered that Compound (I) can exist in multiple crystalline forms (polymorphs). One particular crystalline form, Form II, has been found to be more thermodynamically stable and, thus, likely more suitable for bulk preparation and handling than other polymorphic forms. Efficient and economic methods have been developed to prepare Compound (I) and Form II in high purity on a large scale. In animal studies, Form II has demonstrated safety and efficacy in treating depressive disorders and, when micronized, improved absorption compared to non-micronized Form II.